Step 2 · Review evidence

Review mutation evidence

Filter mutation relevance signals, inspect linked drug-repurposing hypotheses, and check the evidence trace before exporting a report.
5 of 5 mutations·6 hypotheses
Generate report

Research-use only. Expert review and retrospective validation are required.

Research workflow

Inspect signals before reporting

This page is where the researcher checks why each signal or hypothesis is surfaced before turning it into a report.

Export report
Run analysis
2Review evidence
3Export report
4Share client view
Active cohort
5 results

Mutations

Click a row to see drug evidence

RankGeneVariantPathwayEvidencePrototype scoreInterpretationLimitationNext validation
1EGFRL858REGFR/ERBB signallingStrong
94
EGFR L858R is a well-known oncogenic driver signal in lung adenocarcinoma research and is relevant for targeted pathway investigation.The demo signal is not sufficient for clinical action and requires curated evidence review.Confirm variant annotation and compare ranking against curated oncology knowledgebases.
2TP53R175Hp53 tumour suppressor pathwayStrong
88
TP53 R175H is associated with disrupted tumour suppressor function and may affect genomic stability research.TP53 biology is context-specific and does not create a direct candidate class without additional evidence.Review tumour suppressor pathway evidence with an oncology researcher and molecular pathology expert.
3KRASG12CRAS/MAPK signallingModerate
82
KRAS G12C affects RAS/MAPK signalling and is relevant for pathway-level drug-repurposing hypothesis generation.Pathway activation does not imply a real-world response to any candidate class.Benchmark the pathway match against retrospective mutation-drug association datasets.
4ALKRearrangement signalALK tyrosine kinase signallingEmerging
74
ALK rearrangement signals may indicate altered kinase signalling and require confirmatory research workflow checks.A rearrangement signal requires orthogonal confirmation before any real-world interpretation.Verify structural variant support and review evidence provenance.
5METExon 14 skippingRTK/MAPK signallingModerate
72
MET exon 14 skipping alters receptor turnover and may be relevant for kinase-pathway hypothesis review.Requires orthogonal confirmation and curated evidence review.Confirm splicing impact and compare with curated MET evidence.

Drug hypotheses

Evidence detail

EGFR inhibitor class · EGFR

Explainability

EGFR inhibitor class

The cohort contains an EGFR L858R signal mapped to EGFR/ERBB signalling, and the candidate class targets the same oncogenic pathway.

Strong
Matched gene

EGFR

Matched variant

L858R

Matched pathway

EGFR/ERBB signalling

Evidence category

Strong research evidence

Transparent score factors

Target

33

Pathway

28

Prototype

19

Evidence

14

Prototype compatibility layer

Prototype compatibility score: 94. This score is simulated in Phase 2.

Limitation

Requires clinical-trial, guideline, and retrospective evidence review before any real-world interpretation.

Next validation

Compare ranking against curated oncology knowledgebases and expert review.

Matched mutation interpretation

EGFR L858R is a well-known oncogenic driver signal in lung adenocarcinoma research and is relevant for targeted pathway investigation.

Research-use decision support only. This panel supports expert review and retrospective validation planning.